Skip to main content

Table 3 Competing risk model of MACCEs

From: Predictive effect of triglyceride‑glucose index on clinical events in patients with type 2 diabetes mellitus and acute myocardial infarction: results from an observational cohort study in China

 

% (Events)

Unadjusted HR (95% CI)

p value

Adjusted HR (95% CI)

p value

All cause death

 TyG ≤ 8.91

12.8% (83)

Ref

-/-

Ref

-/-

 8.91 < TyG < 9.54

15.8% (101)

1.18 (0.86,1.58)

0.255

1.67 (1.24,2.25)

0.001

 TyG ≥ 9.54

16.7% (108)

1.26 (0.95,1.68)

0.112

2.35 (1.72,3.20)

 < 0.001

CV death

 TyG ≤ 8.91

9.3% (60)

Ref

-/-

Ref

-/-

 8.91 < TyG < 9.54

11.9% (76)

1.24 (0.88,1.73)

0.217

1.60 (1.11,2.30)

0.012

 TyG ≥ 9.54

15.0% (97)

1.60 (1.16,2.20)

0.004

2.71 (1.92,3.83)

 < 0.001

Non-fatal MI

 TyG ≤ 8.91

5.9% (38)

Ref

-/-

Ref

-/-

 8.91 < TyG < 9.54

8.0% (51)

1.29 (0.85,1.96)

0.214

1.37 (0.90,2.10)

0.143

 TyG ≥ 9.54

11.1% (72)

1.93 (1.28,1.90)

0.001

2.02 (1.32,3.11)

0.001

Non-fatal stroke

 TyG ≤ 8.91

3.9% (25)

Ref

-/-

Ref

-/-

 8.91 < TyG < 9.54

3.4% (22)

0.94 (0.52,1.69)

0.830

0.94 (0.50,1.78)

0.859

 TyG ≥ 9.54

4.5% (29)

1.20 (0.69,2.08)

0.529

1.39 (0.73,2.63)

0.315

Cardiac rehospitalization

 TyG ≤ 8.91

11.3% (73)

Ref

-/-

Ref

-/-

 8.91 < TyG < 9.54

17.4% (111)

1.51 (1.13,2.03)

0.006

1.48 (1.10,2.01)

0.011

 TyG ≥ 9.54

26.3% (170)

2.46 (1.87,3.24)

 < 0.001

2.42 (1.81,3.24)

 < 0.001

Revascularization

 TyG ≤ 8.91

6.5% (42)

Ref

-/-

Ref

-/-

 8.91 < TyG < 9.54

10.6% (68)

1.58 (1.08,2.31)

0.020

1.35 (0.90,2.02)

0.142

 TyG ≥ 9.54

18.0% (116)

2.83 (1.99,4.04)

 < 0.001

2.41 (1.63,3.55)

 < 0.001

Composite MACCEs

 TyG ≤ 8.91

27.8% (180)

Ref

-/-

Ref

-/-

 8.91 < TyG < 9.54

37.2% (238)

1.34 (1.10,1.64)

0.004

1.58 (1.33,1.88)

 < 0.001

 TyG ≥ 9.54

49.1% (317)

2.03 (1.68,2.45)

 < 0.001

2.32 (1.92,2.80)

 < 0.001

  1. Adjusted factors included TyG index, age, BMI, history of stroke and PCI, antiplatelet agent used before admission, WBC, hemoglobin, albumin, eGFR, LVEF, angiography findings (LM/three-disease and proximal LAD), in-hospital treatment(PCI/CABG, antiplatelet agent, ACEI/ARB, beta-blocker, statins) and hypoglycemic agents(Metformin, Alpha-glucosidase inhibitor, DPP-4i and insulin)
  2. MACCEs, major adverse cardiac and cerebral events; TyG, triglyceride-glucose index; CV, cardiovascular; MI, myocardial infarction; BMI, body mass index; PCI, percutaneous coronary intervention; WBC,white blood cell; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LM, left main coronary artery; LAD, left anterior descending; CABG, coronary artery bypass graft; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; DPP-4i, dipeptidyl peptidase-4 inhibitor; HR, hazard ratio; CI, confidence interval; Ref, reference